Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 900Other hematologic neoplasm 340Plasma cell 157Myeloid 114Sarcoma 79Dermatologic 64Classical hematology 43CNS 27Genitourinary 22Breast 19Gynecologic 13Other neoplasm 12Thoracic 11Gastrointestinal 9Head & Neck 7Other solid neoplasm 4Endocrine 2NET 1

Conditions

Neuroendocrine Tumors 169Carcinoid Tumor 27Carcinoma, Neuroendocrine 22Neoplasms 16Gastro-enteropancreatic neuroendocrine tumor 16Adenoma, Islet Cell 15Pancreatic Neoplasms 12Neoplasm Metastasis 10Pheochromocytoma 8Paraganglioma 8Sarcoma 7Colorectal Neoplasms 7Carcinoma 7Neuroectodermal Tumors, Primitive 6Neuroblastoma 6Gastrointestinal Neoplasms 6Vipoma 5Somatostatinoma 5Gastrinoma 5Cholangiocarcinoma 5Carcinoma, Islet Cell 5Breast Neoplasms 5Small Cell Lung Carcinoma 4Serotonin Syndrome 4Digestive System Neoplasms 4Anus Neoplasms 4Thyroid Neoplasms 3Salivary Gland Neoplasms 3Ovarian Neoplasms 3Neoplasms by Site 3

Interventions

Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma × NET × Clear all
NCT05396118 2024-05-14

Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients

Rigshospitalet, Denmark

Phase 2 Enrolling by invitation
15 enrolled
BreastEndocrineLymphoidNETSarcoma

Breast Neoplasms, Lymphoma, Sarcoma, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡